| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| GSK plc American Depositary Shares (Each representing two) | Bebtelovimab (LY-CoV1404) and Sotrovimab (VIR-7831 / GSK4182136) - (BLAZE-4) | COVID-19 antibody | Phase 2 | Trial Completed | Intravenous | COVID-19 |
| GSK plc American Depositary Shares (Each representing two) | Covifenz (Medicago) | COVID-19 vaccine | NDA Filing | Intramuscular | COVID-19 | |
| GSK plc American Depositary Shares (Each representing two) | Ventolin (salbutamol) | Metered dose inhaler (MDI) | Phase 3 | Data Released | Inhalation | Respiratory |
| GSK plc American Depositary Shares (Each representing two) | Otilimab (MOR103/GSK3196165) - (ContRAst-3) | Rheumatoid Arthritis | Phase 3 | Withdrawn | Intravenous | Immunology: Anti-TNF |
| GSK plc American Depositary Shares (Each representing two) | Latozinemab (AL001) - (INFRONT-3) | Frontotemporal Dementia | Phase 3 | Trial Discontinued | intravenous | Neurology |
| GSK plc American Depositary Shares (Each representing two) | BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8) | Multiple Myeloma | BLA Filing | Data Released | BLENREP intravenous POMALYST oral Dexamethasone oral | Oncology |
| GSK plc American Depositary Shares (Each representing two) | Bintrafusp alfa | Non-small Cell Lung Cancer | Phase 3 | Intravenous | Oncology | |
| GSK plc American Depositary Shares (Each representing two) | Ensovibep (VIR-7831 / GSK4182136) - (ACTIV-3) | Mild to moderate COVID-19 | Phase 3 | Withdrawn | Intravenous | COVID-19 |